News | August 28, 2023
Gland Pharma receives 2 observations under 483 for Pashamylaram facility
The company is committed to address the observations and will submit its response to US FDA within the stipulated time
The company is committed to address the observations and will submit its response to US FDA within the stipulated time
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
Zinc Sulfate Injection is indicated in adult and paediatric patients as a source of zinc for parenteral nutrition
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators
Centre aims to train surgeons and other healthcare professionals from India and Southeast Asia in robotic-assisted surgery
India will account for about 18% of the Asia-Pacific (APAC) MRI systems market in 2023
The company has entered into a three-year Deferred Prosecution Agreement
The drug will be manufactured at JB Pharma's formulation manufacturing facility in Panoli, Gujarat
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Subscribe To Our Newsletter & Stay Updated
